title: Tapentadol (Palexia) for moderate to severe acute pain.
abstract: Tapentadol (Palexia - Grünenthal) is a recently introduced strong analgesic with µ-agonistic opioid and additional noradrenaline reuptake inhibition properties. The summary of product characteristics (SPC) states that it is indicated for the relief of moderate to severe acute pain in adults, which can be adequately managed only with opioid analgesics.1 Here we review the place of tapentadol in the treatment of patients with moderate to severe acute pain.
mesh_terms: D059787:Acute Pain / Q000517:prevention & control*; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D010636:Phenols / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D017450:Receptors, Opioid, mu / Q000627:therapeutic use*; D000077432:Tapentadol
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D010636:Phenols; D017450:Receptors, Opioid, mu; D000077432:Tapentadol